Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18643718 | 0.83 | — | — | |
| SCHEMBL4797858 | 0.74 | ELANE (0.35) | DGAT1 | |
| SCHEMBL10033375 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL16371938 | 0.72 | — | — | |
| SCHEMBL4877577 | 0.72 | — | — | |
| SCHEMBL17174979 | 0.72 | ALDH1A1 (0.33) | ALDH1A1DGAT1 | |
| SCHEMBL16642287 | 0.69 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL25079139 | 0.67 | — | — | |
| SCHEMBL15834194 | 0.67 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL20643368 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | HOSSAIN NAFIZAL | 2009-12-03 | — | — | US | disclosed |
| US-7524856-B2 | Tricyclic spiroderivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1496836-B1 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7323460-B2 | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| CN-1918160-A | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1699791-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1496836-A4 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050176955-A1 | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| WO-2005061499-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-1496836-A2 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003077857-A2 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003077850-A2 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ACKR3, CXCR1, CXCR2 | ALDH1A1 707/4885DGAT1 2847/4885TSHR 360/4885 |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | ALDH1A1 946/4885DGAT1 3657/4885TSHR 283/4885 |
| US-20050176955-A1 | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors | CDK8, PNP, HINT1 | ALDH1A1 1843/4885DGAT1 4368/4885TSHR 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.